logo conference-reports

Conference Reports

При финансовой поддержке logo MSD Oncology

ASCO-GI 2020 – Esophageal cancer: no survival benefit from boosted radiotherapy dose

The current standard dose for local-regional control in esophageal cancer is lower than that used for other tumor sites.